

# STATE OF WEST VIRGINIA DEPARTMENT OF HUMAN SERVICES BUREAU FOR MEDICAL SERVICES

Alex J. Mayer Cabinet Secretary Cynthia Beane, MSW, LCSW Commissioner

### Pharmaceutical and Therapeutics Committee

#### October 29th, 2025

Location: In person – St John XVIII Pastoral Center 100 Hodges Road Charleston, WV 25314 (304) 558-1700

Time: Open Session 9:00 AM – 10:30 AM EST Time: Executive Session 10:30 AM – 1:30 PM EST Time: Open Session 1:30 PM – 5:00 PM EST

#### **AGENDA**

Therapeutic Class List on Pages 3 and 4

- Call to Order Open Session (Approximately 9:00 AM 10:30 AM) \*times may vary depending on number of public speakers as well as any additional discussion. Call in information for the Open Session is +1 952-222-7450 meeting code 273 427 629#
- II. Welcome and Introductions
- III. Housekeeping Items/Updates
  - i. Approval of August 27th, 2025, Minutes
  - ii. PDL Compliance/Generic Percent Report Updates
- IV. Drug Class Announcements
- V. Chairman Calls for First Round of Extractions
- VI. Public Comments (Agenda classes only limit three minutes per product)
  - i. Speaker Sign-up will begin one hour prior to the start of the P&T Committee meeting (8:00am EST) and will conclude after 45 minutes. Additional information may be found on the WV BMS website under P&T Committee > Speaker Sign-Up Process
    - Pharmaceutical and Therapeutics Committee | Bureau for Medical Services
- VII. Chairman Calls for Second Round of Extractions
- VIII. Motion for All Non-Extracted Categories to be Approved as Proposed



- IX. Executive Session (Approximately from 10:30 AM-1:30 PM)
- X. Lunch Break; approximately 12:30 PM 1:30 PM
- XI. Extracted Therapeutic Category Reviews/Committee Recommendations (Approximately 1:30 PM 5:00 PM/Meeting Adjournment) \*Please use the original information for joining the call remotely: Call in information for the Open Session is +1 952-222-7450 meeting code 273 427 629#
- XII. Next Meeting January 28th, 2026, 2:00 PM 5:00 PM, Virtual Meeting
- XIII. Other Business
- XIV. Adjournment



## Therapeutic Class Reviews recommended by CHC for first round extraction are denoted in **bold, italic** font.

- 1. Acne Agents, Topical
- 2. Alzheimer's Agents
- 3. Analgesics, Narcotics- Long Acting (Non-Parenteral)
- 4. Analgesics, Narcotics- Short Acting (Non-Parenteral)
- 5. Androgenic Agents
- 6. Anesthetics, Topical
- 7. Angiotensin Modulators
- 8. Antianginal & Anti-Ischemic
- 9. Antibiotics, GI & Related Agents
- 10. Antibiotics, Inhaled
- 11. Antibiotics, Topical
- 12. Antibiotics, Vaginal
- 13. Anticoagulants
- 14. Anticonvulsants
- 15. Antidepressant, Other
- 16. Antidepressants, SSRIs
- 17. Antiemetics
- 18. Antifungals, Oral
- 19. Antifungals, Topical
- 20. Antihemophilia Factor Agents
- 21. Antihypertensives, Sympatholytics
- 22. Antihyperuricemics
- 23. Antimigraine Agents, Prophylaxis
- 24. Antimigraine Agents, Acute
- 25. Antiparasitics, Topical
- 26. Antiparkinson's Agents
- 27. Antipsoriatics, Topical
- 28. Antipsychotics, Atypical
- 29. Antiretrovirals
- 30. Antivirals, Oral
- 31. Antivirals, Topical
- 32. Beta Blockers
- 33. Bladder Relaxant Preparations
- 34. Bone Resorption Suppression & Related Agents
- 35. BPH Treatments
- 36. Bronchodilators, Beta Agonists
- 37. Calcium Channel Blockers
- 38. Cephalosporins & Related Antibiotics
- 39. COPD Agents
- 40. Crohn's Disease Oral Steroids

- 41. Cytokine & Cam Antagonists
- 42. Diabetes Agents, Biguanides
- 43. Diabetes Agents, DPP-4 Inhibitors
- 44. Diabetes Agents, GLP-1 Agonists
- 45. Diabetes Agents, Insulin and Related Agents
- 46. Diabetes Agents, Meglitinides
- 47. Diabetes Agents, Miscellaneous Agents
- 48. Diabetes Agents, SGLT2 Inhibitors
- 49. Diabetes Agents, TZD
- 50. Dry Eye Products
- 51. Epinephrine, Self-Injected
- 52. Erythropoiesis Stimulating Proteins
- 53. Fluoroquinolones, Oral
- 54. Glucocorticoids, Inhaled
- 55. Growth Hormones and Achondroplasia Agents
- 56. H. Pylori Treatment
- 57. Heart Failure Treatments
- 58. Hepatitis B Treatments
- 59. Hepatitis C Treatments
- 60. Hyperparathyroid Agents
- 61. Hyperphosphatemia Agents
- 62. Hypoglycemia Treatments
- 63. Immunomodulators, Atopic Dermatitis
- 64. Immunomodulators, Genital Warts & Actinic Keratosis Agents
- 65. Immunosuppressive, Oral
- 66. Intranasal Rhinitis Agents
- 67. Irritable Bowel Syndrome/Short Bowel Syndrome/Selected GI Agents
- 68. Laxatives and Cathartics
- 69. Leukotriene Modifiers
- 70. Lipotropics, Other (Non-Statins)
- 71. Lipotropics, Statins
- 72. MABS Anti-IL/IgE
- 73. Macrolides
- 74. Multiple Sclerosis Agents
- 75. Neuropathic Pain
- 76. NSAIDs
- 77. Obstructive Sleep Apnea Agents
- 78. Ophthalmic Antibiotics



P&T Committee Agenda October 29<sup>th</sup>, 2025 Page 4

- 79. Ophthalmic Antibiotics/Steroid Combinations
- 80. Ophthalmics for Allergic Conjunctivitis
- 81. Ophthalmics, Anti-Inflammatories
- 82. Ophthalmics, Glaucoma Agents
- 83. Opiate Dependence Treatments
- 84. Oral and Topical Contraceptives
- 85. Otic Antibiotics
- 86. PAH Agents
- 87. Pancreatic Enzymes
- 88. Pituitary Suppressive Agents, LHRH
- 89. Platelet Aggregation Inhibitors

- 90. Potassium Removing Agents
- 91. Progestins for Cachexia
- 92. Proton Pump Inhibitors
- 93. Sedative Hypnotics
- 94. Skeletal Muscle Relaxants
- 95. Steroids, Topical
- 96. Stimulants & Related Agents
- 97. Tetracyclines
- 98. Ulcerative Colitis Agents
- 99. Vaginal Ring Contraceptives
- 100. Vasodilators, Coronary
- 101. VMAT Inhibitors

